NeoGenomics Third Quarter 2026 Earnings Call - NEOGENOMICS INC

Financial Performance:

• Total revenue reached $209 million in Q3 2026, growing 11% year-over-year (YoY), exceeding expectations.
• Clinical revenue grew 13% to $295 million, driven by a 2% increase in test volumes and an 11% increase in Average Unit Price (AUP).
• NGS revenue surged 29% YoY, fueled by 17% volume growth and 25%+ growth in large-panel tests.
• Adjusted gross margin expanded by over 300 basis points to 49%, resulting in adjusted gross profit of $102 million.
• Adjusted EBITDA rose 53% YoY to $18.7 million ($19 million).
• Non-clinical revenue was $15 million, declining 10% YoY due to the exit of a high-volume, low-value customer and legacy pharma contracts.
• Cash and cash equivalents ended the quarter at $139 million, down $6 million due to a $10 million DOJ settlement payment, temporary receivables impacts from the Zyfin RCM transition, and capital expenditures.

Guidance and Future Outlook:

• Raised 2026 full-year revenue guidance to $807–$809 million (midpoint ~11% growth) from previous $802–$806 million.
• Updated 2026 adjusted EBITDA guidance to ~$60 million, up from $56–$58 million, representing ~40% YoY growth.
• Anticipates full-year adjusted gross margin improvement of over 150 basis points, with Q4 margins expected around 48%.
• Expects NGS revenue growth to exceed 25% for 2026, approaching $250 million.
• Projects 2027 revenue growth in the low teens for clinical business, with NGS volume growth normalized to mid-single digits after the temporary drag from the departed contract.
• Long-term outlook targets NGS and MRD combining for two-thirds of revenue, with MRD expected to ramp meaningfully in 2028.
• Management plans to host an investor day in the first half of 2027.

Business Segments and Product Lines:

• NGS: Strong momentum driven by product upgrades (Neocomprehensive Heme panel now detects variants at 3% allele fraction) and the PanTracer family (Solid Tumor) seeing strong uptake and managed care reimbursement tailwinds.
• MRD (RadarST): Achieved Medicare coverage for immunotherapy (IO) monitoring in August (3rd indication); two additional indications under review with potential approval by year-end and mid-2027. ~30% of RadarST orders attach to other Neogenomics tests.
• Non-Clinical: Oncology Data Solutions (ODS) remains a high-margin growth opportunity; legacy pharma testing is being rationalized by exiting commoditized, low-margin contracts.
• Lab of the Future: Upgrading to the NovaSeq X platform for the Heme NGS portfolio planned for H1 2027; expanded digital pathology partnership with Indica Labs to leverage AI for operational efficiency and diagnostics.
• RCM: Transitioning to the Zyfin revenue cycle management platform to improve collection rates and automate workflows, with temporary receivables impacts expected to normalize in Q4 2027.

Market and Competitive Landscape:

• Estimated 60% of patients in the community setting (where 80% seek care) still do not receive advanced comprehensive genomic profiling, representing a significant addressable market.
• Community therapy selection penetration for large-panel NGS estimated at 35–40%, leaving substantial room for growth.
• Differentiation strategy focuses on integrated portfolio offerings (diagnosis to surveillance) in the community oncology channel, competing with large CLIA labs through workflow simplification and broad test menus.
• MRD total addressable market (TAM) for U.S. tumor-informed testing estimated at nearly $4 billion; securing Medicare and commercial payer coverage is critical for expansion.
• Strategic focus remains on "portfolio mindset" to drive attachment rates between NGS and MRD products.

Risks and Challenges:

• Reimbursement Risks: Dependence on expanding Medicare and commercial payer coverage for RadarST (currently only partial indications covered).
• Operational Transition: Temporary impact on receivables and cash flow due to the Zyfin RCM platform implementation.
• Government Pricing: Potential headwinds from 2027 CMS reimbursement rate adjustments, though exposure is estimated at low-to-mid single-digit millions.
• Customer Concentration: Exit of a single high-volume, low-value legacy contract created a temporary headwind to revenue growth.
• Execution Risk: Need to successfully execute the CEO transition and maintain momentum without disruption.

Management Commentary and Tone:

• Leadership Transition: CEO Tony Zuck announced he will step down effective January 4, 2027, succeeded by COO Warren Stone; Zuck will become Executive Chair. The transition is described as a "position of strength" with Zuck remaining actively involved.
• Confidence: Management expressed high confidence in the strategy, citing strong momentum, durable NGS growth, and successful operational initiatives.
• Strategy Continuity: Warren Stone emphasized continuity in strategy, noting he was a key architect of current initiatives; the focus remains on accelerating execution of the existing roadmap.
• Tone: Optimistic and decisive, with a clear focus on moving up the value chain and away from commoditized services.

Analyst Questions and Answers:

• Leadership Transition: Analysts noted the timing; Management confirmed the decision was made to ensure continuity and that Stone has been deeply involved in strategy for years.
• AUP Sustainability: AUP growth was 11% in Q3; Management expects this to normalize to mid-single digits as the one-time impact of the low-value contract exit fades. Future growth will be driven by high-margin mix shifts and RCM initiatives.
• NGS Growth Drivers: Growth is attributed to sales force expansion, new product launches (2023 panels now contributing ~25% of revenue), and mix shift to large panels.
• MRD Adoption: ~30% attach rate to other tests; volumes are growing month-over-month post-Medicare approval. Commercial payer expansions (including a leading regional plan) are underway.
• 2027 Outlook: Management declined to provide specific 2027 guidance but expects clinical volume growth to normalize and non-clinical business to potentially return to slight positive growth in 2027.
• Margins: Margins are expected to continue expanding due to mix shift, RCM benefits, and Lab of the Future efficiencies (NovaSeq X impact expected H2 2027/2028).

Other Key Points:

• Sales Force: Ended Q3 with >160 sales resources; plans to expand further in H2 2027 and 2028, particularly for NGS and MRD.
• Investment Priorities: Increased R&D spending (approx. 7% of revenue vs. 4-5% previously) to drive indication growth and data asset monetization; disciplined G&A reduction to offset these investments.
• Data Asset: The Oncology Data Solutions (ODS) business is growing in double digits with high margins, leveraging a robust database of genomics and image data.
• AI Integration: Partnership with Indica Labs aims to use AI for digital pathology interpretation to improve operational efficiency and support diagnostic decisions.
• Product Pipeline: Next-generation whole-gene MRD assay expected for clinical launch in 2029.